Critical Quality Attribute Monitoring and Control in Drug Substance Manufacturing II

Chair(s):
Clark, P., Scale-up Systems Inc.
Co-chair(s):
Wu, H., FDA/CDER

Developing robust drug substance production processes to ensure patient safety and drug efficacy is dependent on the sound understanding and control of the drug substance quality attributes relevant for clinical performance and drug product manufacture. This understanding is then translated into the design of the drug substance manufacturing process and a relevant monitoring and control system to ensure that quality attributes within the desired ranges are consistently obtained. This session covers drug substance critical quality attribute identification, characterization, and monitoring systems for both drug substance quality and manufacturing process control. Authors are encouraged to highlight clinically relevant specifications for drug substance and innovative control strategies for drug substance manufacturing.

Papers:

Checkout

Paper abstracts are public but to access Extended Abstracts, you must first purchase the conference proceedings.

Checkout

Do you already own this?

Pricing


Individuals

AIChE Members $150.00
AIChE Graduate Student Members Free
AIChE Undergraduate Student Members Free
Non-Members $225.00